Park Avenue Securities LLC Has $8.83 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Park Avenue Securities LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 7.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 102,657 shares of the company's stock after purchasing an additional 7,103 shares during the quarter. Park Avenue Securities LLC's holdings in Novo Nordisk A/S were worth $8,831,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Novare Capital Management LLC raised its position in shares of Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock valued at $325,000 after buying an additional 85 shares in the last quarter. Steel Grove Capital Advisors LLC raised its holdings in Novo Nordisk A/S by 2.3% in the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock valued at $541,000 after acquiring an additional 86 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in Novo Nordisk A/S by 2.6% in the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company's stock valued at $493,000 after acquiring an additional 87 shares in the last quarter. Rosenberg Matthew Hamilton lifted its position in shares of Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company's stock valued at $454,000 after acquiring an additional 94 shares during the period. Finally, Burns J W & Co. Inc. NY grew its holdings in shares of Novo Nordisk A/S by 1.9% during the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company's stock worth $647,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded up $0.34 during midday trading on Thursday, reaching $83.26. 6,320,240 shares of the company were exchanged, compared to its average volume of 8,102,344. Novo Nordisk A/S has a one year low of $80.05 and a one year high of $148.15. The stock has a market cap of $373.61 billion, a P/E ratio of 26.94, a PEG ratio of 0.92 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock's 50-day moving average price is $98.82 and its 200-day moving average price is $117.93.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.